Astellas To Acquire Ocata Therapeutics
Astellas Pharma has agreed to acquire Ocata Therapeutics, Inc., a biotechnology company focused on the research and development of regenerative medicines, primarily cell therapies, for approximately $379 million. Under the agreement, Astellas will acquire Ocata through Laurel Acquisition Inc., a wholly owned subsidiary of Astellas US Holding, Inc. The boards of directors of both Astellas and Ocata have unanimously approved the agreement. Under the agreement, Laurel will commence a tender offer for all outstanding shares of common stock of Ocata, for a price of $8.50 per share in cash. Upon successful completion of the tender offer, Laurel will be merged into Ocata, and any remaining shares of common stock of Ocata will be canceled and converted into the right to receive the offer price (except for shares held by stockholders who properly demand appraisal rights under Delaware law). The board of directors of Ocata has resolved to recommend that Ocata’s stockholders tender into the tender offer.
Each of the directors and executive officers of Ocata entered into support agreements with Astellas and Laurel, pursuant to which such directors and officers, among other things, agreed to tender the shares of common stock of Ocata that they hold into the tender offer. Shares held by these directors and officers represent, in the aggregate, approximately 1.7% of the share of common stock of Ocata outstanding on this date.
Source: Astellas Pharma